Probiotix Health PLC Directorate Change (2910Z)
January 11 2024 - 1:00AM
UK Regulatory
TIDMPBX
RNS Number : 2910Z
Probiotix Health PLC
11 January 2024
ProBiotix Health plc
( "ProBiotix" or the "Company")
Directorate change
ProBiotix Health p lc (AQUIS: PBX), a life sciences busi ness d
eveloping probiotics to support cardiometabolic health, announces
that Mikkel Hvid-Hansen, Commercial Director and Board member of
the Company, has resigned from his position to pursue other
opportunities, effective from 28 February 2024.
Separately, the Company announces the appointment of Michael
Litichevski as Head of Global Sales as of 1 January 2024. The
appointment of Michael is part of the Company's strategy to build a
strong commercial team to support the long-term growth of
ProBiotix. Michael joins ProBiotix from Lactobio, a microbial
solutions and microbiome skincare company with a live bacteria
business. He has over 25 years' experience in building B2B segments
with more than 11 years of this specifically within the probiotics
dietary supplements industry. He was previously VP of Sales at
Deerland Probiotics & Enzymes, VP sales of Bifodan and has
worked for large organisations such as Orkla brands and Nycomed.
Michael has e xtensive experience with the commercialisation of
innovative and high-quality probiotic solutions which is in line
with the Company's strategical direction of finished supplement
dosage format. He has good connections in the industry and has the
ability to create strong and valuable partnerships.
Steen Andersen, CEO of ProBiotix Health plc commented: "We are
sad to see Mikkel leave us but wish him well in his future
endeavours. He has held the role of European Sales Director and
Commercial Director at ProBiotix for the last four years, since
before we listed on Aquis, and has brought a wealth of knowledge
and expertise to the role. The Board would like to thank him for
his service and guidance.
"We would also like to extend a warm welcome to Michael as our
new Head of Global Sales. I am confident that he will be a huge
asset to the commercial team and will greatly contribute to
building our B2B business both locally and globally. He b rings
vast experience in sales leadership combined with scientific
knowledge from global leading probiotic companies to support
ProBiotix's strategy and sales on an international level. "
For further information, please contact:
ProBiotix Health plc https://probiotixhealth-ir.com/
Steen Andersen, Chief Executive Contact via Walbrook
below
Peterhouse Capital Limited (Aquis Corporate Tel: 020 7469 0930
Adviser and Broker)
Mark Anwyl
Duncan Vasey
Walbrook PR Ltd probiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Market Abuse Regulation (MAR) Disclosure
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms
part of retained EU law (as defined in the European Union
(Withdrawal) Act 2018).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXEALFEFFDLEFA
(END) Dow Jones Newswires
January 11, 2024 02:00 ET (07:00 GMT)
Probiotix Health (AQSE:PBX)
Historical Stock Chart
From Feb 2025 to Mar 2025
Probiotix Health (AQSE:PBX)
Historical Stock Chart
From Mar 2024 to Mar 2025